NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2016
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TROXYCA ER is an extended-release oral capsule combining naltrexone hydrochloride (an opioid antagonist) with oxycodone hydrochloride (an opioid agonist), designed to reduce abuse potential while maintaining analgesia. It is indicated for management of moderate to severe chronic pain in opioid-tolerant patients. The combination mechanism aims to deter misuse by blocking euphoric effects if the capsule is tampered with.
LOE Approaching1.5 years to LOE
With LOE approaching in 2027 and minimal linked job activity, this product likely operates with a lean, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on TROXYCA ER at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.